Tatiana Cobo-Ibáñez, Gemma Mora Ortega, Carlos Sánchez-Piedra, Gonzalo Serralta-San Martín, Israel J Thuissard-Vasallo, Vanesa Lores Gutiérrez, Llanos Soler Rangel, Cristina García Yubero, Ana Esteban-Vázquez, Elena López-Aspiroz, Cristina Andreu Vázquez, Inmaculada Toboso, Blanca María Martínez Alonso de Armiño, Rocío Alejandra Olivares Alviso, Rocío Calderón Nieto, Cecilia Yañez, Marlín Alejandra Zakhour González, Tatiana Sainz Sánchez, Silvia Arroyo de la Torre, Nazaret Del Amo Del Arco, Jorge Francisco Gómez-Cerezo, Teresa Ramírez Prieto, Alicia Martínez Hernández, Santiago Muñoz-Fernández
Post-COVID-19 interstitial lung disease (ILD) is a new entity that frequently causes pulmonary fibrosis and can become chronic. We performed a single-center parallel-group open-label pilot randomized clinical trial to investigate the efficacy and safety of cyclosporine A (CsA) in the development of ILD in the medium term among patients hospitalized with COVID-19 pneumonia. Patients were randomized 1:1 to receive CsA plus standard of care or standard of care alone. The primary composite outcome was the percentage of patients without ILD 3 months after diagnosis of pneumonia and not requiring invasive mechanical ventilation (IMV) (response without requiring IMV)...
February 15, 2024: Scientific Reports